Enso 15 mg (Capsule (Enteric Coated))

Indications

• Short term treatment of active duodenal ulcer
• Maintenance of healed duodenal ulcers
• Short term treatment of active benign gastric ulcers
• Short term treatment of active erosive esophagitis
• Maintenance of healing of erosive esophagitis
• Pathological hypersecretory conditions including Zollinger-Ellison Syndrome
• H. pylori eradication to reduce the risk of duodenal ulcer recurrence

Pharmacology

• Substituted benzimidazole
• PPI property to block the final step of acid secretion
• Inhibits H+/K+ ATPase enzyme system
• Inhibition of both basal and stimulated acid

Dosage & Administration

• Benign gastric ulcer: 30 mg daily in the morning for 8 weeks
• Duodenal ulcer: 30 mg daily in the morning for 4 weeks; maintenance 15 mg
• NSAID-associated duodenal or gastric ulcer: 15-30 mg daily for 4 weeks
• Zollinger-Ellison syndrome: Initially 60 mg once daily adjusted according to response; daily doses of 120 mg or more is given in two divided doses
• Gastroesophageal reflux disease: 30 mg daily in the morning for 4 weeks
• Acid-related dyspepsia: 15-30 mg daily in the morning for 2-4 weeks

Interaction

• Selective inhibitor of the cytochrome P-450 monooxygenase system
• Effect on hepatic clearance
• Uncertainty over the effect on the oral combined contraceptive pill
• Influence on bacterial colonization of the stomach and duodenum
• Influence on vitamin B12 absorption

Contraindications

• Known hypersensitivity to any component of the formulation

Side Effects

• Possible induction of carcinoid tumors
• Rise in serum gastrin levels
• Long term treatment with a proton pump inhibitor in patients with Helicobacter pylori infection may accelerate the development of atrophic gastritis
• Dose dependent diarrhea
• Headache

Pregnancy & Lactation

• Avoided in pregnancy unless there are compelling reasons

Precautions & Warnings

• Gastric malignancy should be ruled out
• Hepatic impairment
• Pregnancy and lactation

Use in Special Populations

• Neonates: Not recommended for use with neonates
• Children: The youngest person to have received Enso in clinical trials was 13 years old
• The Elderly: No increase in adverse drug reaction

Therapeutic Class

• Proton Pump Inhibitor

Storage Conditions

• Store at 25°C

Related Brands